Lack of insulin resistance in fibroblasts from subjects with polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 47, Issue 8, 1998, Pages 940-946

  Ciaraldi, Theodore P ^a   Morales, Arlene J ^a   Hickman, Matthew G ^a   Odom Ford, Rosanne ^a   Yen, Samuel S C ^a   Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; FIBROBLAST; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; INSULIN BINDING; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

EID: 0031880952     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90348-1     Document Type: Article

References (55)

1. Yen SCC: The polycystic ovary syndrome. Clin Endocrinol 12:177-207, 1980
2. Franks S: Polycystic ovary syndrome. N Engl J Med 333:853-861, 1995
3. Franks S, Kiddy D, Sharp P, et al: Obesity and polycystic ovary syndrome. Ann NYAcad Sci 626:201-206, 1991
4. Dunaif A: Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 98:33S-39S, 1995 (suppl 1A)
5. Chang RJ, Nakamura RM, Judd HL, et al: Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359, 1983
6. Holte J, Bergh T, Berne C, et al: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 78:1052-1058, 1994
7. Olefsky JM, Ciaraldi TP, Kolterman OG, et al: Mechanisms of insulin resistance in obesity and non-insulin-dependent diabetes mellitus: Role of receptor and post-receptor defects, in Skyler JS (ed): Insulin Update. Amsterdam, The Netherlands, Excerpta Medica, 1982, pp 41-73
8. Ciaraldi TP, El-Roeiy A, Madar Z, et al: Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 75:577-583, 1992
9. Dunaif A, Segal KR, Shelley DR, et al: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257-1266, 1992
10. Ciaraldi TP, Morales AJ, Hickman MG, et al: Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 82:1421-1425, 1997
11. Rosenbaum D, Haber RS, Dunaif A: Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 264:E197-E202, 1993
12. Marsden PJ, Murdoch A, Taylor R: Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome. Metabolism 43:1536-1542, 1994
13. Polderman KH, Gooren JG, Asscheman H, et al: Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79:265-271, 1994
14. Holmang A, Larsson B-M, Brezezinska Z, et al: Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 262:E851-E855, 1992
15. Buffington CK, Givens JR, Kitabchi AE: Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes 40:693-700, 1991
16. Wells A, Sutcliffe I, Johnson A, et al: Abnormal activation of glycogen synthesis in fibroblasts from NIDDM subjects (evidence for an abnormality specific to glucose metabolism). Diabetes 42:583-589, 1993
17. Eckel RH, Fujimoto WY: Insulin-stimulated glucose uptake, leucine incorporation into protein, and uridine incorporation into RNA in skin fibroblast cultures from patients with diabetes mellitus. Diabetologia 20:186-189, 1981
18. Thornburn AW, Gumbiner B, Bulacan F, et al: Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522-529, 1990
19. Steil GM, Volund A, Kahn SE, et al: Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42:250-256, 1993
20. Saad MF, Anderson RL, Laws A, et al: A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43:1114-1121, 1994
21. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738, 1971
22. Ciaraldi TP, Molina JM, Olefsky JM: Insulin action kinetics in adipocytes from obese and noninsulin-dependent diabetes mellitus subjects: Identification of multiple cellular defects in glucose transport. J Clin Endocrinol Metab 72:876-882, 1991
23. Rodbell M: Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375-380, 1964
24. Hirsch J, Gallian E: Methods for the determination of adipose cell size in man and animals. J Lipid Res 9:110-119, 1968
25. Olefsky JM, Kao M: Surface binding and rates of internalization of 1251-insulin in adipocytes and IM-9 lymphocytes. J Biol Chem 257:8667-8673, 1982
26. Whitesell RR, Gliemann J: Kinetic parameters of 3-O-methylglucose and glucose in adipocytes. J Biol Chem 254:5276-5283, 1979
27. Prince MJ, Tsai P, Olefsky JM: Insulin binding, internalization and insulin receptor regulation in fibroblasts from type II, non-insulin-dependent diabetic subjects. Diabetes 30:596-600, 1981
28. Baldwin D, Prince M, Tsai P, et al: Insulin binding, internalization, and receptor regulation in cultured human fibroblasts. Am J Physiol 241:E251-E260, 1981
29. Ciaraldi TP, Goldberg M, Odom R, et al: In vitro effects of amylin on carbohydrate metabolism in liver cells. Diabetes 41:975-981, 1992
30. McClain DA, Maegawa H, Thies RS, et al: Dissection of the growth versus metabolic effects of insulin and insulin-like growth factor-I in transfected cells expressing kinase-defective human insulin receptors. J Biol Chem 265:1678-1682, 1990
31. Zaninetti D, Greco-Perotto R, Assimacopoulos-Jeannet F, et al: Dysregulation of glucose transport and transporters in perfused hearts of genetically obese (fa/fa) rats. Diabetologia 32:56-60, 1989
32. Smith U, Eriksson J, Lonnroth P: Receptors for insulin-like growth factors. J Intern Med 225:43-45, 1989
33. Sinha MK, Buchanan C, Leggett N, et al: Mechanism of IGF-1-stimulated glucose transport in human adipocytes. Demonstration of specific IGF-1 receptors not involved in stimulation of glucose transport. Diabetes 38:1217-1225, 1989
34. Podskalny JM, Kahn CR: Insulin activation of glycogen synthase in cultured human fibroblasts is not mediated solely via the insulin receptor. Horm Metab Res 18:335-340, 1986
35. Mueckler M: Facultative glucose transporters. Eur J Biochem 219:713-725, 1994
36. Sorbara LR, Tang Z, Cama A, et al: Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism 43:1568-1574, 1994
37. Conway GS, Avet C, Rumsby G: The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum Reprod 9:1681-1683, 1994
38. Moller DE, Flier JS: Insulin resistance-mechanisms, syndromes and implications. N Engl J Med 325:938-949, 1991
39. Dunaif A, Xia J, Book C-B, et al: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J Clin Invest 96:801-810, 1995
40. Vidal-Puig A, Munoz-Torres M, Garcia-Calventa C, et al: Reduction of endogenous, ovarian and adrenal androgens with ketconazole does not alter insulin response in the polycystic ovary syndrome. J Endocrinol Invest 17:647-652, 1994
41. Nagamani M, Van Dinh T, Kelver ME: Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 154:384-389, 1986
42. Legro RS: The genetics of polycystic ovary syndrome. Am J Med 98:9S-16S, 1995 (suppl 1A)
43. Jahanfar S, Eden JA, Warren P, et al: A twin study of polycystic ovary syndrome. Fertil Steril 63:478-486, 1995
44. Poretsky L, Piper B: Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 84:613-621, 1994
45. Willis D, Franks S: Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-1 insulin-like growth factor receptor. J Clin Endocrinol Metab 80:3788-3790, 1995
46. 125I] insulin-like growth factor I binding in the rat. Endocrinology 122:581-585, 1988
47. Homburg R, Pariente C, Lunenfeld B, et al: The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IG-FBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 7:1379-1383, 1992
48. Insler V, Barash A, Shoham Z, et al: Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease. Isr J Med Sci 30:42-47, 1994
49. Fendri S, Arlot S, Marcelli JM, et al: Relationship between insulin sensitivity and circulating sex hormone binding globulin levels in hyperandrogenic obese women. Int J Obes 18:755-759, 1994
50. Velazquez EM, Mendoza S, Hamer T, et al: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654, 1994
51. Dunaif A, Scott D, Finegood D, et al: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
52. Meirow D, Yossepowitch O, Rosler A, et al: Insulin resistant and nonresistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod 10:1951-1956, 1995
53. Ciampelli M, Fulghesu AM, Cucinelli F, et al: Heterogeneity in β cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 12:1897-1901, 1997
54. Morales AR, Laughlin GA, Butzow T, et al: Insulin, somatotropic, and lutenizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab 81:2854-2864, 1996
55. Dunaif A, Sorbara L, Delson R, et al: Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean Hispanic women. Diabetes 42:1462-1468, 1993